Case study

02 Feb 2021

Hematologic Malignancies Case Study


Overview

Successful Study Start-up for complex Phase I Gene Modified Advanced Therapy Medicinal Product (ATMP) TCR-T (cell immunotherapy) study during the COVID-19 pandemic.


    Study Specifics

    Countries: Netherlands, 1 site
    Services: Full service
    Type: Dose Escalation, Open Label, gene-modified Advanced Therapy Medicinal Product (ATMP) / Genetically Modified Organisms (GMO) TCR-T in various malignant hematology diseases

    See Other Case Studies

    TFS involved in European global customer’s pre-lau...

    TFS was requested to prepare and conduct a Late Phase global proposal to support the pre-launch activities of two pro...

    Read more

    How TFS Strategic Resourcing Solutions deployed a ...

    Given the catastrophic spread of COVID-19, the search for safe and effective therapies has taken on an unpreced...

    Read more

    TFS & a Global Biotech Company

    As clinical trials grow increasingly complex, timelines shorten, and R&D costs soar. Today’s biopharmaceuti...

    Read more